What question did this study set out to answer?

To summarize the preclinical and clinical evidence leading to the FDA approval of belumosudil for patients with chronic graft-versus-host disease.

May 1, 2022Drugs of today

Belumosudil for chronic graft-versus-host disease

View Full Paper

Ask AI

Bookmark

Authors

BTBreanna J Taylor JCJaimie Cohen JTJennifer Tejeda

Discussion

Member takes

Overview

Narrative review reveals the efficacy and safety of belumosudil in chronic graft-versus-host disease, highlighting its role as the first approved selective ROCK2 inhibitor.

Key Points

To summarize the preclinical and clinical evidence leading to the FDA approval of belumosudil for patients with chronic graft-versus-host disease.
Review of preclinical investigations assessing the ROCK signaling pathway, its isoform selectivity, and downstream fibrotic and inflammatory mechanisms.
Evaluation of clinical safety and efficacy data for belumosudil mesylate in adults and pediatric patients aged 12 years and older refractory to at least two prior systemic therapies.
Belumosudil selectively inhibits the ROCK2 isoform, avoiding the dose-limiting toxicities typically observed with non-selective ROCK inhibitors.
Clinical evaluation demonstrated favorable safety and efficacy profiles, securing FDA approval for patients aged 12 years and older after failure of at least two prior lines of systemic therapy.

Cite This Study

Taylor et al. (2022) studied this question.

synapsesocial.com/papers/6ab37ca8b1df9c50c8ec6ff6 https://doi.org/10.1358/dot.2022.58.5.3400705

View Full Paper

Ask AI

Bookmark

May 1, 2022Drugs of today

Belumosudil for chronic graft-versus-host disease

View Full Paper

Ask AI

Bookmark

Authors

BTBreanna J Taylor JCJaimie Cohen JTJennifer Tejeda

Discussion

Member takes

Overview

Narrative review reveals the efficacy and safety of belumosudil in chronic graft-versus-host disease, highlighting its role as the first approved selective ROCK2 inhibitor.

Key Points

To summarize the preclinical and clinical evidence leading to the FDA approval of belumosudil for patients with chronic graft-versus-host disease.
Review of preclinical investigations assessing the ROCK signaling pathway, its isoform selectivity, and downstream fibrotic and inflammatory mechanisms.
Evaluation of clinical safety and efficacy data for belumosudil mesylate in adults and pediatric patients aged 12 years and older refractory to at least two prior systemic therapies.
Belumosudil selectively inhibits the ROCK2 isoform, avoiding the dose-limiting toxicities typically observed with non-selective ROCK inhibitors.
Clinical evaluation demonstrated favorable safety and efficacy profiles, securing FDA approval for patients aged 12 years and older after failure of at least two prior lines of systemic therapy.

Cite This Study

Taylor et al. (2022) studied this question.

synapsesocial.com/papers/6ab37ca8b1df9c50c8ec6ff6 https://doi.org/10.1358/dot.2022.58.5.3400705

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark